

Dengue Fever Hits the North America Home Front

Montréal, Canada, March 4th, 2011. Bio-Solutions Corp. (BISU: OTCBB), A biotech marketing company, that sell and distributes, GreenEx™, an FDA approved organic mosquito larvicide, along with NutraAnimal™, an organic livestock feed is proud to give a company update.

The second confirmed case domestically of Dengue Fever has been confirmed (<http://www.nbcmiami.com/news/local/Second-Miami-Dade-Dengue-Fever-Case-Confirmed-117246333.html>). Dengue Fever is a painful sometimes deadly disease transferred by infected Mosquito's. Annually, over 100 million cases of Dengue are reported worldwide.

This is the 2nd confirmed case in America, in over 50 Years. The first case was reported in November 2010.

“As North American's we sometimes forget, how lucky we are to have the great healthcare that we do. We must eradicate the disease's that we do know how to treat”. Every year Mosquito transferred Disease's , attribute to the death of millions of lives.

Bio-Solutions Corp is currently positioned to capture a big percentage of this business. **GREENEX™** our flagship product is produced from a strain of *Bacillus thuringiensis* subspecies *israelensis* (Bti), a naturally occurring bacterium that produces a crystalline protein toxin. The larval activity of **GREENEX™** formulations and all other Bti formulations is due to the presence of the protein toxin. We have achieved a 98% efficacy rate, and are in ongoing negotiations, to implement our products, on a Municipal and State level.

Over the past year management at Bio-Solutions Corp have been expanding out our workforce and is working with various African Nations to Implement GreenEx™, and NutraAnimal™ Livestock Feed.

To Date Bio-Solutions Corp has representatives in The Republic of Congo, Mali, Burkina Faso and Niger.

“The Year 2011, is about growth for Bio-Solutions Corp” stated Gilles Chaumillon President and CEO. “Along with the countries we are dealing with and where we have great contacts, we plan on expanding into new markets. Please look forward to more regular company updates”, stated Dr Chaumillon.

For more information on Bio-Solutions Corp. and its products, please visit the company's website at www.biosolutionscorp.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of studies, the ability of the Company to take advantage of business opportunities in the biotechnology

industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.

Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.

Contact: Investor & Public Relations

Jakub Hryniewicz

(708) 829-4585

ir@bio-solutionscorp.com